Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

New England Journal of Medicine

Volumn 339, Issue 14, 1998, Pages 947-952

  Glorieux, Francis H ^a,b   Bishop, Nicholas J ^a,b   Plotkin, Horacio ^a   Chabot, Gilles ^a   Lanoue, Ginette ^a   Travers, Rose ^a  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; PAMIDRONIC ACID;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DEFORMATION; BONE DENSITY; BONE MINERAL; BONE PAIN; BONE TURNOVER; CHILD; CHRONIC PAIN; CLINICAL ARTICLE; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPENIA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ALKALINE PHOSPHATASE; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; CALCIUM; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS IMPERFECTA; PAIN; PERIODICITY;

EID: 0032190352     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810013391402     Document Type: Article

References (28)

1. Sykes B, Ogilvie D, Wordsworth P, et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 1990;46:293-307.
2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-16.
3. Cattell HS, Clayton B. Failure of anabolic steroids in the therapy of osteogenesis imperfecta: a clinical, metabolic, and biochemical study. J Bone Joint Surg Am 1968;50:123-41.
4. Albright JA, Grunt JA. Studies of patients with osteogenesis imperfecta. J Bone Joint Surg Am 1971;53:1415-25.
5. Castells S. New approaches to treatment of osteogenesis imperfecta. Clin Orthop 1973;93:239-49.
6. Pedersen U, Charles P, Hansen HH, Elbrond O. Lack of effects of human calcitonin in osteogenesis imperfecta. Acta Orthop Scand 1985;56: 260-4.
7. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16:360-3.
8. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 1988;8:71-2.
9. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:266-83.
10. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997;131:622-5.
11. Glorieux FH, Travers R, Chabot G, Lanoue G. Bone histomorphometric analysis in osteogenesis imperfecta. J Bone Miner Res 1994;9:Suppl 1:S226. abstract.
12. Glorieux FH, Bishop NJ, Travers R, et al. Type V osteogenesis imperfecta. J Bone Miner Res 1997;12:Suppl 1:S389. abstract.
13. Wimalawansa SJ, Gunasekera RD. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. Calcif Tissue Int 1993; 53:237-41.
14. Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 1987;217:79-98.
15. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford, Calif.: Stanford University Press, 1959.
16. Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop 1981;159:111-22.
17. Garn SM, Poznanski AK, Larson K. Metacarpal lengths, cortical diameters and areas from the 10-state nutrition survey including: estimated skeletal weights, weight, and stature for whites, blacks, and Mexican-Americans. In: Jaworski ZFG, ed. Proceedings of the first workshop on bone morphometry. Ottawa, Ont.: University of Ottawa Press, 1976:367-91.
18. Underwood LE, Van Wyk JJ. Normal and aberrant growth. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. 8th ed. Philadelphia: W.B. Saunders, 1992:1079-138.
19. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996;14:158-70.
20. Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983;17:204-7.
21. Brenner RE, Vetter U, Bollen A-M, Mörike M, Eyre DR. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 1994;9:993-7.
22. Plotkin H, Nunez M, Alvarez Filgueira ML, Zanchetta JR. Lumbar spine bone density in Argentine children. Calcif Tissue Int 1996;58:144-9.
23. Davie MWJ, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child 1994;70: 331-4.
24. Reinus WR, McAlister WH, Schranck F, Chines A, Whyte MP. Differing lumbar vertebral mineralization rates in ambulatory pediatric patients with osteogenesis imperfecta. Calcif Tissue Int 1998;62:17-20.
25. Frost HM. Vital biomechanics: proposed general concepts for skeletal adaptations to mechanical usage. Calcif Tissue Int 1988;42:145-56.
26. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-4.
27. Oliveri MB, Mautalen CA, Rodriguez Fuchs CA, Romanelli MC. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J 1991;39:45-8.
28. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int 1992;50:36-41.